StockData
Attovia Therapeutics, Inc. logo

Attovia Therapeutics, Inc. (ATTO) stock

ATTONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 9, 2026
$15.10−0.48 (-3.08%)

Close on Nov 20, 2026Market cap $689.33MP/E –Yield –

Attovia Therapeutics gross profit

Gross profit is revenue minus the direct cost of the goods and services sold.

No gross profit figures for Attovia Therapeutics

Attovia Therapeutics has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

More Attovia Therapeutics figures

See a number that looks wrong?